Trial Profile
An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron in naïve Patients With Chronic Hepatitis B and D Co-infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2008 Planned patient number (67) added as reported by ClinicalTrials.gov.
- 20 Jun 2008 New trial record.